Kim Sutton Golodetz joined LHA’s healthcare practice in 1998. Drawing from more than 15 years of Wall Street experience, including several years as a sell-side securities analyst, she provides her clients with first-hand perspective on how the Street evaluates companies, how analysts build their models and, most importantly, how managements’ communications affect credibility and valuation. LHA clients have utilized Kim’s experience as a corporate relations manager at the American Stock Exchange to navigate through listing-related issues. During her tenure at LHA, Kim has guided many clients through introductions and investment banking relationships in support of IPOs, follow-on offerings and PIPEs that led to approximately half a billion dollars in funds raised. She is a full-service IR practitioner and her capabilities run the gamut from traditional tactics – including the preparation of written materials, such as conference call scripts, presentations, press releases and corporate Fact Sheets – to consulting on corporate positioning. As a long-time veteran of LHA’s healthcare practice, Kim has knowledge of various FDA regulatory pathways, including Pre-market Approvals, New Drug Applications, Abbreviated New Drug Applications and 510(k) Applications.
She was previously director of investor relations for a microcap company during a change in management and business focus from a biotechnology company to a drug delivery/medical device company.
Kim received a BA in English from the State University of New York at Albany and an MBA in International Business and Finance from Pace University.